Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Fortress Biotech Surged After Reporting Big Success With CAR-T Cancer Approach

Shares of Fortress Biotech (formerly known as Coronado Biosciences) surged after the company announced that a glioblastoma patient who showed no response to standard of care treatments had a remarkable turnaround after being treated with the company’s Phase I drug candidate, MB-101.

Read More »

Provectus Fires Peter Culpepper as Interim CEO and COO

For the second time in less than a year, Provectus Biopharmaceuticals Inc. is down a chief executive officer.

Read More »

FTC requires divestitures in Boehringer-Sanofi deal

Boehringer Ingelheim agreed to divest five types of animal health products to settle charges that a proposed asset swap with Sanofi would harm competition.

Read More »

Medtronic must face revived U.S. lawsuit over Infuse

A federal appeals court revived a lawsuit accusing Medtronic Plc of defrauding shareholders by covering up negative side effects from its Infuse bone growth product for nearly a decade.

Read More »

Up-and-Coming Tedor Pharma Expands and Adds New Jobs

Tedor Pharmaceuticals is expanding its Rhode Island manufacturing facility and expanding its employment with more than 20 new positions, the company announced.

Read More »

A Turnaround: Regeneron Eyes a Comeback in 2017

After suffering a setback in 2016, Regeneron could be poised for a turnaround in 2017 and it hinges on correcting manufacturing problems that caused regulators to block approval of a new drug to treat rheumatoid arthritis.

Read More »

Top Harvard Scientist Retracts Diabetes Breakthrough Paper

A Harvard professor has retracted research that was once considered a breakthrough in diabetes research.

Read More »

Serial testers and cursory checks: India’s flawed generic drug trials business

The serial testing of some volunteers is raising new questions about the level of oversight of India’s generic drug trials industry, after some CROs came under recent international regulatory scrutiny.

Read More »

Anthera’s cystic fibrosis drug fails late-stage study, shares tank

Anthera Pharmaceuticals Inc. said its drug to treat certain cystic fibrosis patients failed a late-stage study, sending the company’s shares tumbling nearly 70 percent in after-hours trading.

Read More »

U.S. posts rules for addressing cyber bugs in medical devices

The U.S. government issued rules for addressing cyber vulnerabilities in medical devices, providing manufacturers with guidelines for fixing security bugs in equipment, including pacemakers, insulin pumps and imaging systems.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom